We are live on ! Find out more
IMNP

Immune Pharmaceuticals Inc.
IMNP

Delisted

IMNP was delisted on the 25th of July, 2018.

Back to rankings

13 hedge funds and large institutions have $172K invested in Immune Pharmaceuticals Inc. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

6% less capital invested

Capital invested by funds: $183K → $172K (-$11.1K)

24% less funds holding

Funds holding: 17 → 13 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
+$71K
2
Renaissance Technologies
Renaissance Technologies
New York
+$39.1K
3
Barclays
Barclays
United Kingdom
+$25.5K
4
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
+$2.83K
5
CS
Credit Suisse
Switzerland
+$1.41K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$10K
2
Bank of America
Bank of America
North Carolina
-$8K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$5K
5
UBS Group
UBS Group
Switzerland
-$4.42K
Name Holding Trade Value Shares
Change 		Change in
Stake
CH
1
CVI Holdings
Delaware
$47K +$71K +251,029 New
Barclays
2
Barclays
United Kingdom
$35K +$25.5K +90,271 +93%
Vanguard Group
3
Vanguard Group
Pennsylvania
$26K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$26K +$39.1K +138,205 New
EDRH
5
Edmond de Rothschild Holding
Switzerland
$16K +$636 +2,250 +3%
CS
6
Credit Suisse
Switzerland
$7K +$1.41K +5,000 +15%
IP
7
Intellectus Partners
California
$6K – – –
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.21K +$2.83K +10,000 +56%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4K – – –
Goldman Sachs
10
Goldman Sachs
New York
– -$10K -28,405 Closed
Bank of America
11
Bank of America
North Carolina
– -$8K -23,514 Closed
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
– -$6K -16,858 Closed
UBS Group
13
UBS Group
Switzerland
– -$4.42K -15,643 -100%
Bank of New York Mellon
14
Bank of New York Mellon
New York
– -$5K -14,670 Closed
AG
15
Advisor Group
Arizona
– -$1K -3,750 Closed
Morgan Stanley
16
Morgan Stanley
New York
– -$777 -2,746 -100%

IMNP Hedge Fund Activity: Q2 2018 in Review

13 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q2 2018, worth a combined $172K — down 6.1% from $183K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IMNP and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was CVI Holdings, opening a new position worth an estimated $71K. The largest seller was Goldman Sachs, exiting entirely with an estimated $10K sold.

  • 13 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q2 2018, down from 17 in Q1 2018.
  • Funds reported $172K of Immune Pharmaceuticals Inc. stock for Q2 2018, down 6.1% quarter-over-quarter.
  • 2 funds opened new Immune Pharmaceuticals Inc. positions in Q2 2018 and 6 closed out, a net change of -4 holders.
  • The largest Immune Pharmaceuticals Inc. buyer in Q2 2018 was CVI Holdings, an estimated $71K added.
  • The largest Immune Pharmaceuticals Inc. seller in Q2 2018 was Goldman Sachs, an estimated $10K sold.

Based on aggregated 13F filings for Q2 2018.